



CBD MED RESEARCH CORP

#810 – 675 W. Hastings Street, Vancouver, B.C., Canada V6B 1N2
Tel: 604-802-7551 • www.cbdmedresearch.com

CBD Med Research announces Private Placement and Share Consolidation

May 10, 2017, Vancouver, British Columbia – CBD Med Research Corp. (“CBM” or the “Company”) announces that it is offering on a private placement basis up to 3,333,333 common shares of the Company at a price of \$0.15 per share for total proceeds of up to C\$500,000 on a post consolidated basis. The proceeds from the financing will be used for general working capital.

The Company will pay a 6% fee on all or a portion of the financing.

Share Consolidation

The Company further announces that it proposes to consolidate its issued and outstanding common shares on the basis of every Four (4) pre-consolidation common shares into one (1) post-consolidation common share (the “**Consolidation**”). The Company currently has 14,386,418 common shares issued and outstanding. Upon the Consolidation becoming effective, the Company will have approximately 3,596,605 common shares issued and outstanding on a non-diluted basis, prior to rounding down for fractional shares. The Company’s outstanding warrants will be adjusted on the same ratio (4:1) in accordance with their respective terms, with proportionate adjustments being made to exercise prices.

The Consolidation is subject to regulatory approval, including the approval of the TSX Venture Exchange.

Closing of the private placement is subject to stock exchange approval.

ON BEHALF OF THE BOARD

“Gary Zak”

Gary F. Zak, Chief Executive Officer

For further information, please contact: Gary Zak: gzak@shaw.ca or 604-802-7551

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.